Rishabh Jain, Medical Consultant at Renova Hospital (RHL), shared on X:
“Our correspondence is now published in the New England Journal of Medicine!
TALAPRO-3: Are we treating metastatic prostate cancer earlier, or overtreating patients sooner?
Talazoparib with enzalutamide improves radiographic PFS. But important questions remain:
- Overall survival benefit remains unproven (HR 0.77).
- Only 10% of control patients subsequently received a PARP inhibitor.
- Grade ≥3 anemia: 51%.
- Blood transfusions: 40%.
The key question: Is upfront PARP inhibition superior to an optimized sequential strategy?
We raised this concern in NEJM, and the TALAPRO-3 investigators, including Neeraj Agarwal and Karim Fizazi, responded.
A valuable scientific exchange on efficacy, toxicity, sequencing, and the future of precision oncology.”
Title: PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer
Authors: Lorenzo D’Antiga, Angelo Di Giorgio, Giuseppe Ronzitti, Sem Aronson, Ulrich Beuers, Nicola Brunetti-Pierri, Alessandro Rossi, Piter Bosma, Philippe Veron, Fanny Collaud, Eric Guemas, Nathalie Knuchel-Legendre, Beatrice Beaurain, Manon Sanz, Maria Abou-Samra, Arnaud Valent, Ji Gao-Desliens, Gerald Perret, Philippe Labrune, Federico Mingozzi
You can also read:
What’s New On Radiotherapy of Prostate Cancer in 2026?
